Xerient
Next Generation Treatment of Pancreatic Cancer
Startup · IsraelXerient is a Petah Tikva-based startup in the Health Tech & Life Sciences sector, established in 2019. Next Generation Treatment of Pancreatic Cancer. The company has raised a total of $5.03M across 3 funding rounds, currently at the Seed stage. Xerient was founded by Guy Yachin. The company has 1-10 employees.
With $5.03M in total funding, Xerient is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQPetah Tikva
- Last RoundUndisclosed
Guy YachinCo-founder & CEO
What does Xerient do?
Xerient is focused on unmet needs in cancer treatment, particularly in abdominal and gastrointestinal cancers. Xerient is pursuing the development of novel therapeutics and diagnostic technologies that can dramatically improve the survival of these patients. The company is introducing a portfolio of products that will address hard to treat cancers in the abdominal/GI area, beginning with solutions for pancreatic cancer.
How much funding has Xerient raised?
Xerient has raised $5.03M in total funding across 3 rounds. The company is currently at the Seed stage.
Who founded Xerient?
Xerient was founded in 2019 by Guy Yachin (Co-founder & CEO).
What sector is Xerient in?
Xerient operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development. Target customers: Healthcare & Life Sciences, Healthcare, Providers.
Where is Xerient located?
Xerient is based in Petah Tikva, Israel.